Trade Novartis - CHF - NOVN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.40 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.015699% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.006523% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | CHF | ||||||||
Margin | 5% | ||||||||
Stock exchange | Switzerland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Novartis AG ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 92.5 |
Open* | 91.85 |
1-Year Change* | 21.66% |
Day's Range* | 91.55 - 92.15 |
52 wk Range | 73.32-93.95 |
Average Volume (10 days) | 2.27M |
Average Volume (3 months) | 55.31M |
Market Cap | 202.26B |
P/E Ratio | 27.73 |
Shares Outstanding | 2.07B |
Revenue | 47.30B |
EPS | 3.20 |
Dividend (Yield %) | 3.61052 |
Beta | 0.96 |
Next Earnings Date | Oct 24, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 22, 2023 | 91.60 | 0.00 | 0.00% | 91.60 | 92.20 | 91.25 |
Sep 21, 2023 | 92.50 | -0.20 | -0.22% | 92.70 | 93.80 | 92.10 |
Sep 20, 2023 | 92.75 | 0.20 | 0.22% | 92.55 | 93.20 | 91.95 |
Sep 19, 2023 | 91.60 | 0.65 | 0.71% | 90.95 | 92.15 | 90.45 |
Sep 18, 2023 | 91.70 | 0.05 | 0.05% | 91.65 | 92.40 | 91.25 |
Sep 15, 2023 | 92.05 | 0.55 | 0.60% | 91.50 | 92.75 | 90.65 |
Sep 14, 2023 | 90.15 | 0.35 | 0.39% | 89.80 | 91.10 | 89.65 |
Sep 13, 2023 | 89.15 | -0.15 | -0.17% | 89.30 | 89.95 | 88.40 |
Sep 12, 2023 | 88.95 | 0.85 | 0.96% | 88.10 | 90.05 | 88.10 |
Sep 11, 2023 | 88.20 | 0.55 | 0.63% | 87.65 | 88.45 | 87.35 |
Sep 8, 2023 | 87.95 | 0.10 | 0.11% | 87.85 | 88.30 | 87.35 |
Sep 7, 2023 | 88.25 | 1.60 | 1.85% | 86.65 | 88.40 | 86.65 |
Sep 6, 2023 | 87.00 | -0.05 | -0.06% | 87.05 | 87.05 | 85.85 |
Sep 5, 2023 | 87.75 | -0.65 | -0.74% | 88.40 | 88.90 | 87.25 |
Sep 4, 2023 | 88.80 | -0.25 | -0.28% | 89.05 | 89.60 | 88.20 |
Sep 1, 2023 | 89.10 | 0.15 | 0.17% | 88.95 | 89.35 | 88.40 |
Aug 31, 2023 | 87.85 | -1.80 | -2.01% | 89.65 | 89.75 | 87.85 |
Aug 30, 2023 | 89.90 | -0.55 | -0.61% | 90.45 | 90.45 | 89.60 |
Aug 29, 2023 | 90.20 | -0.25 | -0.28% | 90.45 | 90.75 | 89.50 |
Aug 28, 2023 | 90.35 | 0.75 | 0.84% | 89.60 | 91.15 | 89.60 |
Novartis - CHF Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, October 24, 2023 | ||
Time (UTC) 06:30 | Country CH
| Event Q3 2023 Novartis AG Earnings Release Q3 2023 Novartis AG Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
Time (UTC) 10:59 | Country CH
| Event Novartis AG Impact & Sustainability Annual Event Novartis AG Impact & Sustainability Annual EventForecast -Previous - |
Wednesday, November 15, 2023 | ||
Time (UTC) 10:59 | Country CH
| Event Novartis AG at UBS European Conference Novartis AG at UBS European ConferenceForecast -Previous - |
Time (UTC) 10:59 | Country CH
| Event Novartis AG at Wolfe Research Healthcare Conference Novartis AG at Wolfe Research Healthcare ConferenceForecast -Previous - |
Tuesday, November 28, 2023 | ||
Time (UTC) 10:59 | Country CH
| Event Novartis AG R&D Day Novartis AG R&D DayForecast -Previous - |
Wednesday, March 6, 2024 | ||
Time (UTC) 09:00 | Country CH
| Event Novartis AG Annual Shareholders Meeting Novartis AG Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 51742 | 52877 | 49898 | 48624 | 46017 |
Revenue | 51742 | 52877 | 49898 | 48624 | 46017 |
Cost of Revenue, Total | 14998 | 15435 | 14400 | 13930 | 13555 |
Gross Profit | 36744 | 37442 | 35498 | 34694 | 32462 |
Total Operating Expense | 42545 | 41188 | 39746 | 39538 | 31824 |
Selling/General/Admin. Expenses, Total | 14190 | 14815 | 14093 | 14319 | 13690 |
Research & Development | 9088 | 9041 | 8484 | 8386 | 8154 |
Depreciation / Amortization | 158 | 109 | 64 | 50 | 179 |
Unusual Expense (Income) | 3402 | 1173 | 2503 | 2284 | -4309 |
Other Operating Expenses, Total | 449 | 653 | 538 | 607 | 549 |
Operating Income | 9197 | 11689 | 10152 | 9086 | 14193 |
Interest Income (Expense), Net Non-Operating | -543 | 14628 | -146 | -36 | -5 |
Other, Net | -283 | -180 | -128 | -110 | -93 |
Net Income Before Taxes | 8371 | 26137 | 9878 | 8940 | 14095 |
Net Income After Taxes | 6955 | 24018 | 8071 | 7147 | 12800 |
Minority Interest | 0 | 3 | 1 | -5 | -3 |
Net Income Before Extra. Items | 6955 | 24021 | 8072 | 7142 | 12797 |
Net Income | 6955 | 24021 | 8072 | 11732 | 12611 |
Income Available to Common Excl. Extra. Items | 6955 | 24021 | 8072 | 7142 | 12797 |
Income Available to Common Incl. Extra. Items | 6955 | 24021 | 8072 | 11732 | 12611 |
Dilution Adjustment | |||||
Diluted Net Income | 6955 | 24021 | 8072 | 11732 | 12611 |
Diluted Weighted Average Shares | 2197 | 2260 | 2296 | 2319 | 2344 |
Diluted EPS Excluding Extraordinary Items | 3.16568 | 10.6288 | 3.51568 | 3.07978 | 5.45947 |
Dividends per Share - Common Stock Primary Issue | 3.46171 | 3.19907 | 3.38945 | 3.04815 | 2.90402 |
Diluted Normalized EPS | 4.47075 | 11.1183 | 4.40641 | 3.86715 | 3.79006 |
Total Extraordinary Items | 4590 | -186 | |||
Interest Expense (Income) - Net Operating | 260 | -38 | -336 | -38 | 6 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 13936 | 13208 | 13001 | 12842 | 13085 |
Revenue | 13936 | 13208 | 13001 | 12842 | 13085 |
Cost of Revenue, Total | 4006 | 3829 | 3837 | 3657 | 3749 |
Gross Profit | 9930 | 9379 | 9164 | 9185 | 9336 |
Total Operating Expense | 11016 | 10352 | 11052 | 10674 | 10857 |
Selling/General/Admin. Expenses, Total | 3673 | 3401 | 3699 | 3404 | 3589 |
Research & Development | 2349 | 2272 | 2318 | 2263 | 2251 |
Depreciation / Amortization | 45 | 153 | 42 | 42 | 39 |
Interest Expense (Income) - Net Operating | 29 | 46 | -28 | 90 | 96 |
Unusual Expense (Income) | 858 | 298 | 1145 | 1068 | 996 |
Other Operating Expenses, Total | 56 | 353 | 39 | 150 | 137 |
Operating Income | 2920 | 2856 | 1949 | 2168 | 2228 |
Interest Income (Expense), Net Non-Operating | -226 | -212 | -222 | -219 | -202 |
Other, Net | 75 | 96 | 14 | -30 | 16 |
Net Income Before Taxes | 2769 | 2740 | 1741 | 1919 | 2042 |
Net Income After Taxes | 2317 | 2294 | 1466 | 1575 | 1695 |
Minority Interest | -1 | -1 | 0 | -2 | -1 |
Net Income Before Extra. Items | 2316 | 2293 | 1466 | 1573 | 1694 |
Net Income | 2316 | 2293 | 1466 | 1573 | 1694 |
Income Available to Common Excl. Extra. Items | 2316 | 2293 | 1466 | 1573 | 1694 |
Income Available to Common Incl. Extra. Items | 2316 | 2293 | 1466 | 1573 | 1694 |
Diluted Net Income | 2316 | 2293 | 1466 | 1573 | 1694 |
Diluted Weighted Average Shares | 2095 | 2120 | 2158 | 2180 | 2211 |
Diluted EPS Excluding Extraordinary Items | 1.10549 | 1.0816 | 0.67933 | 0.72156 | 0.76617 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 3.46171 | 0 | 0 |
Diluted Normalized EPS | 1.45098 | 1.20956 | 1.14055 | 1.12553 | 1.14122 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 36910 | 45718 | 29673 | 29504 | 35563 |
Cash and Short Term Investments | 18726 | 28113 | 11293 | 11234 | 15718 |
Cash | 2877 | 3396 | 3750 | 3247 | 3121 |
Cash & Equivalents | 4640 | 9011 | 5908 | 7865 | 10150 |
Short Term Investments | 11209 | 15706 | 1635 | 122 | 2447 |
Total Receivables, Net | 9894 | 9621 | 10036 | 10337 | 11036 |
Accounts Receivable - Trade, Net | 8066 | 8005 | 8217 | 8301 | 8739 |
Total Inventory | 7175 | 6666 | 7131 | 5982 | 6956 |
Prepaid Expenses | 911 | 1102 | 943 | 898 | 812 |
Other Current Assets, Total | 204 | 216 | 270 | 1053 | 1041 |
Total Assets | 117453 | 131795 | 127778 | 118370 | 145563 |
Property/Plant/Equipment, Total - Net | 12195 | 13106 | 13939 | 13746 | 15696 |
Property/Plant/Equipment, Total - Gross | 26304 | 28708 | 29894 | 28676 | 34028 |
Accumulated Depreciation, Total | -14109 | -15602 | -15955 | -14930 | -18332 |
Goodwill, Net | 29301 | 29595 | 29999 | 26524 | 35294 |
Intangibles, Net | 31644 | 34182 | 36809 | 28787 | 38719 |
Long Term Investments | 1606 | 2268 | 11611 | 10538 | 9789 |
Note Receivable - Long Term | 948 | 973 | 922 | 624 | 908 |
Other Long Term Assets, Total | 4849 | 5953 | 4825 | 8647 | 9594 |
Total Current Liabilities | 28656 | 30208 | 33059 | 28264 | 29607 |
Accounts Payable | 5146 | 5553 | 5403 | 5424 | 5556 |
Accrued Expenses | 5334 | 5100 | 5336 | 5058 | 5105 |
Notes Payable/Short Term Debt | 3635 | 3606 | 7319 | 4844 | 6430 |
Current Port. of LT Debt/Capital Leases | 2492 | 2896 | 2558 | 2248 | 3190 |
Other Current Liabilities, Total | 12049 | 13053 | 12443 | 10690 | 9326 |
Total Liabilities | 58111 | 64140 | 71180 | 62896 | 66949 |
Total Long Term Debt | 21782 | 24523 | 27978 | 22056 | 22470 |
Long Term Debt | 20244 | 22902 | 26259 | 20353 | 22470 |
Deferred Income Tax | 2686 | 3070 | 3141 | 5867 | 7475 |
Minority Interest | 81 | 167 | 68 | 77 | 78 |
Other Liabilities, Total | 4906 | 6172 | 6934 | 6632 | 7319 |
Total Equity | 59342 | 67655 | 56598 | 55474 | 78614 |
Common Stock | 890 | 901 | 913 | 936 | 944 |
Retained Earnings (Accumulated Deficit) | 63540 | 70989 | 57157 | 59274 | 82191 |
Treasury Stock - Common | -92 | -48 | -53 | -80 | -69 |
Unrealized Gain (Loss) | -198 | 206 | |||
Other Equity, Total | -4798 | -4187 | -1419 | -4656 | -4658 |
Total Liabilities & Shareholders’ Equity | 117453 | 131795 | 127778 | 118370 | 145563 |
Total Common Shares Outstanding | 2119.61 | 2234.94 | 2256.82 | 2265.01 | 2311.17 |
Capital Lease Obligations | 1538 | 1621 | 1719 | 1703 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 32114 | 36910 | 36954 | 38142 | 37236 |
Cash and Short Term Investments | 12260 | 18930 | 19103 | 19758 | 18814 |
Cash & Equivalents | 12000 | 7517 | 8726 | 3625 | 13852 |
Short Term Investments | 260 | 11413 | 10377 | 16133 | 4962 |
Total Receivables, Net | 9183 | 8334 | 8680 | 8910 | 8678 |
Accounts Receivable - Trade, Net | 8916 | 8066 | 8422 | 8643 | 8409 |
Total Inventory | 7886 | 7175 | 6779 | 6880 | 6997 |
Other Current Assets, Total | 2785 | 2471 | 2392 | 2594 | 2747 |
Total Assets | 112241 | 117453 | 118464 | 122910 | 125218 |
Property/Plant/Equipment, Total - Net | 12348 | 12195 | 11731 | 12206 | 12861 |
Goodwill, Net | 29481 | 29301 | 28668 | 29113 | 29636 |
Intangibles, Net | 30451 | 31644 | 31888 | 33367 | 34853 |
Long Term Investments | 2555 | 2554 | 2491 | 2580 | 2906 |
Other Long Term Assets, Total | 5292 | 4849 | 6732 | 7502 | 7726 |
Total Current Liabilities | 30549 | 28656 | 28160 | 27646 | 29807 |
Accounts Payable | 5426 | 5146 | 4693 | 4969 | 5083 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 7166 | 6127 | 7204 | 7247 | 6902 |
Other Current Liabilities, Total | 17957 | 17383 | 16263 | 15430 | 17822 |
Total Liabilities | 60182 | 58111 | 57644 | 59985 | 63678 |
Total Long Term Debt | 21985 | 21782 | 21235 | 23784 | 24373 |
Long Term Debt | 20396 | 20244 | 19732 | 22232 | 22796 |
Capital Lease Obligations | 1589 | 1538 | 1503 | 1552 | 1577 |
Deferred Income Tax | 2727 | 2686 | 2719 | 3122 | 3384 |
Minority Interest | 83 | 81 | 78 | 81 | 164 |
Other Liabilities, Total | 4838 | 4906 | 5452 | 5352 | 5950 |
Total Equity | 52059 | 59342 | 60820 | 62925 | 61540 |
Common Stock | 842 | 890 | 890 | 890 | 901 |
Retained Earnings (Accumulated Deficit) | 51253 | 58544 | 60000 | 62095 | 60699 |
Treasury Stock - Common | -36 | -92 | -70 | -60 | -60 |
Total Liabilities & Shareholders’ Equity | 112241 | 117453 | 118464 | 122910 | 125218 |
Total Common Shares Outstanding | 2097.4 | 2119.61 | 2150.98 | 2182.79 | 2212.58 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 6955 | 24018 | 8071 | 7147 | 12800 |
Cash From Operating Activities | 14236 | 15071 | 13650 | 13625 | 14272 |
Cash From Operating Activities | 1873 | 1807 | 2088 | 1852 | 1783 |
Amortization | 5308 | 4306 | 4376 | 3974 | 3428 |
Non-Cash Items | 4404 | -11714 | 3842 | 3369 | -2315 |
Cash Taxes Paid | 1975 | 2342 | 1833 | 1876 | 1506 |
Cash Interest Paid | 696 | 664 | 703 | 793 | 816 |
Changes in Working Capital | -4304 | -3346 | -4727 | -2717 | -1424 |
Cash From Investing Activities | 1468 | 4208 | -13182 | -2226 | -5591 |
Capital Expenditures | -2671 | -2971 | -2585 | -2257 | -2648 |
Other Investing Cash Flow Items, Total | 4139 | 7179 | -10597 | 31 | -2943 |
Cash From Financing Activities | -20562 | -16264 | -2208 | -13627 | -4244 |
Financing Cash Flow Items | 55 | 94 | -199 | 3307 | -119 |
Total Cash Dividends Paid | -7506 | -7368 | -6987 | -6645 | -6966 |
Issuance (Retirement) of Stock, Net | -10552 | -3004 | -2094 | -5332 | -1336 |
Issuance (Retirement) of Debt, Net | -2559 | -5986 | 7072 | -4957 | 4177 |
Foreign Exchange Effects | -32 | -266 | 286 | 69 | -26 |
Net Change in Cash | -4890 | 2749 | -1454 | -2159 | 4411 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 2294 | 6955 | 5489 | 3914 | 2219 |
Cash From Operating Activities | 2957 | 14236 | 10125 | 5404 | 1649 |
Cash From Operating Activities | 377 | 7181 | 5233 | 3207 | 1405 |
Amortization | 1619 | ||||
Non-Cash Items | 1085 | 4404 | 3417 | 2164 | 918 |
Cash Taxes Paid | 348 | 1975 | 1559 | 1239 | 633 |
Cash Interest Paid | 123 | 696 | 475 | 308 | 110 |
Changes in Working Capital | -2418 | -4304 | -4014 | -3881 | -2893 |
Cash From Investing Activities | 10621 | 1468 | 2935 | -2263 | 9365 |
Capital Expenditures | -470 | -2671 | -2024 | -1442 | -859 |
Other Investing Cash Flow Items, Total | 11091 | 4139 | 4959 | -821 | 10224 |
Cash From Financing Activities | -9202 | -20562 | -16568 | -11830 | -9528 |
Financing Cash Flow Items | -169 | 55 | 99 | 97 | 22 |
Total Cash Dividends Paid | -7255 | -7506 | -7506 | -7506 | -7506 |
Issuance (Retirement) of Stock, Net | -2727 | -10552 | -7874 | -5156 | -2448 |
Issuance (Retirement) of Debt, Net | 949 | -2559 | -1287 | 735 | 404 |
Foreign Exchange Effects | 107 | -32 | -173 | -93 | -41 |
Net Change in Cash | 4483 | -4890 | -3681 | -8782 | 1445 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.3489 | 121820582 | 0 | 2022-12-31 | LOW |
Sandoz Family | Other Insider Investor | 3.9138 | 89135960 | 0 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.7121 | 61766714 | 296752 | 2023-07-31 | LOW |
UBS Asset Management (Switzerland) | Investment Advisor | 2.4548 | 55906821 | 176139 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.3806 | 54217976 | 0 | 2022-12-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 2.1663 | 49335879 | -677105 | 2022-12-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.9274 | 43897216 | 21743 | 2023-07-31 | LOW |
Zürcher Kantonalbank (Asset Management) | Bank and Trust | 1.1612 | 26446726 | 118560 | 2023-07-31 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.8719 | 19856757 | 66327 | 2023-07-31 | LOW |
Artisan Partners Limited Partnership | Investment Advisor | 0.7614 | 17341049 | 362533 | 2023-06-30 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 0.7467 | 17006670 | -3098900 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5902 | 13441576 | 3568 | 2023-07-31 | LOW |
Capital Research Global Investors | Investment Advisor | 0.5743 | 13079359 | -7484 | 2023-06-30 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.5467 | 12450739 | 284839 | 2023-07-31 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.5323 | 12122921 | 37703 | 2023-04-30 | LOW |
California Public Employees' Retirement System | Pension Fund | 0.5222 | 11892523 | 2527466 | 2022-06-30 | LOW |
Nuveen LLC | Pension Fund | 0.3751 | 8543005 | 47653 | 2023-07-31 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 0.3554 | 8095235 | -17005 | 2023-06-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.3527 | 8032113 | 3765 | 2023-05-31 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.2998 | 6828283 | -276205 | 2023-07-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Novartis - CHF Company profile
Novartis AG (NVS) is a global pharmaceutical company. Founded in 1996 through a merger of Ciba-Geigy and Sandoz, Novartis is headquartered in Basel, Switzerland. The firm has two divisions: Innovative Medicines and Sandoz.
Innovative Medicines offer prescription medicines and create treatments in areas of respiratory, ophthalmology, neuroscience, immunology, hepatology, dermatology, cardiovascular, renal and metabolism.
Sandoz develops, manufactures and markets generic pharmaceuticals and biosimilars. Sandoz products include: Adakveo (crizanlizumab), Afinitor Disperz/Votubia (everolimus) and Arzerra (ofatumumab) for Oncology; and Aimovig (erenumab) for neuroscience.
In 2020, in response to the pandemic, the company collaborated with Molecular Partners to develop ensovibep, a DARPin therapeutic candidate designed for potential use against Covid-19.
The company’s shares have been listed on the New York Stock Exchange (NYSE) since 2000. Novartis AG stock is traded under the ticker symbol NVS. You can track live NVS share value and price history at Capital.com.
Industry: | Pharmaceuticals (NEC) |
Lichtstrasse 35
BASEL
BASEL-STADT 4056
CH
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com